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CHAPTER 1: Introduction 
Skin cancer is the most common form of cancer in the world.1,2,3  It is generally split 
between two main categories: melanoma from melanocytes, and non-melanoma skin cancer 
(NMSC), which consists of basal cell and squamous cell carcinomas.  Melanoma is the least 
common, but the most malignant.  Basal cell carcinoma (BCC) is the most benign and also the 
most prevalent.  It accounts for 80% of all skin cancers, making it the most common form of any 
cancer in the world.1  BCC presents as a “flat, firm, pale areas” or “small, raised, pink or red bumps 
that may bleed after a minor injury.”1,2  Treatment often involves surgical removal of the affected 
area and can leave disfiguring scars, especially in cases of large tumors.1  Additionally, scarring 
from tumors located in regions around the eyes, ears, and mouth may be structurally 
compromising and aesthetically displeasing.4  Instances of BCC are increasing, and because of its 
prevalence and recurrence, the cost to healthcare is tremendous.  Over the last decade or so the 
cost of treating skin cancer has jumped from $3.6 billion to $8.1 billion annually, an increase of 
126.6%.  Of that, NMSC accounted for an increase from $2.7 to $4.8 billion.3  For these reasons, 
non-invasive outpatient treatments for basal cell carcinoma are of great interest.4   
Vitamin D3 supplementation is often considered in the treatment of cancer, including BCC, 
due to its well-documented anti-proliferative effects.5,6  In the absence of vitamin D signaling, 
mice exposed to ultraviolet (UV) light develop skin cancer, underscoring its importance.7,8  
Indeed, the regulatory role of vitamin D most likely evolved from a necessity to protect against 
the harmful effects of UV light.6  However, while adequate levels may be protective, 
supplementation may not necessarily add additional benefit.  Animal and cell culture studies 
have in fact found protective effects of vitamin D in several forms of cancer models, and clinical 
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studies of supplementation have been positive in cases of breast and colorectal cancer.8,9  
Unfortunately, human clinical studies of BCC have been rare and inconclusive as to its actual 
benefit, and intervention studies are essentially non-existent.  Analysis of two prospective cohort 
studies found no association between dietary vitamin D intake and BCC occurrence in men or 
women.10,11  Another study found an inverse relationship between serum levels of the circulating 
form of vitamin D and NMSC in elderly men.12  On the other hand, studies have also shown that 
high serum levels actually increase the risk of developing BCC.13,14  The data is further confounded 
because of the varied impact of vitamin D3 on multiple signaling pathways and the mutagenic 
nature of the cancer.  More data is needed to elucidate the actual effects of vitamin D treatment 
in BCC.   
Vitamin D is a general term for a group of fat soluble vitamins that are most notably 
responsible for calcium homeostasis in the body.15  The most common forms are vitamin D2 
(ergocalciferol) and D3 (cholecalciferol), and it is D3 that shows promise in the treatment of 
cancer.  The metabolism of vitamin D3 involves several steps that occur in different organs (Figure 
1.1).  The body is capable of synthesizing 7-dehydrocholesterol in the skin, however, this form of 
the vitamin requires UV light to convert it to cholecalciferol.  Cholecalciferol can also be provided 
in the diet by a limited number of foods, such as eggs and fortified milk.6,16  It is this form that is 
referred to as vitamin D3, although it still requires the addition of two hydroxyl groups before it 
is biologically active.  Cholecalciferol first must travel to the liver, where the enzyme vitamin D 
25-hydroxylase (25-OHase) converts it to 25-hydroxycholecalciferol, also known as calcidiol.  
Next, the vitamin precursor travels to the kidneys, where the enzyme 25-hydroxyvitamin D3 1-
alpha-hydroxylase (1α-OHase) converts it to 1,25-dihydroxycholecalciferol, or calcitriol.6,16  This 
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is the active form, which is capable of binding the vitamin D receptor (VDR), a transcription factor 
that controls the expression of over 900 genes, many of which are involved in cell cycle 
regulation, differentiation, and apoptosis.17  Therefore, vitamin D3 and its receptor may play an 
important role in the treatment of cancer, possibly by way of controlling cellular proliferation.   
One theory behind vitamin D3 supplementation in cases of BCC is that by providing 
additional vitamin D3 one can prevent uncontrolled cell growth by encouraging VDR-induced 
inhibition of cellular proliferation.  Also present in the kidneys is an enzyme called 25-
hydroxyvitamin D3-24-hydroxylase (24-OHase), which adds a third hydroxyl group to vitamin D3.  
This enzyme is up-regulated in response to calcitriol, and results in its inactivation and 
degradation to calcitroic acid.6,16  High expression of 24-hydroxylase was associated with poor 
survival in lung cancer patients.17  Interestingly, all three of these enzymes are also expressed in 
the skin, demonstrating the importance of a reliable balance of vitamin D3 in this organ, perhaps 
as an immediate defense mechanism against the harmful effects of UV radiation.18 
 
Figure 1.1 Vitamin D3 metabolism 
 
 
One of the signaling cascades that VDR regulates is the mTOR pathway (Figure 1.2).  The 
mammalian target of rapaycin (mTOR) is a major control switch involved in cell survival, growth, 
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and proliferation.  mTOR phosphorylates its targets, S6K and 4EBP, which results in the activation 
of protein synthesis.19  This pathway is often up-regulated in cancer, whereas down-regulation is 
associated with differentiation and apoptosis.  Therefore, compounds that can negatively 
regulate the mTOR pathway have the potential to be powerful anti-cancer drugs.  When calcitriol 
binds to VDR, one of the genes that is up-regulated is DNA-damage-inducible transcript 4 (DDIT4), 
also known as regulated in development and DNA damage response 1 (REDD1).19  REDD1 
activates TSC1 and TSC2.  These proteins are responsible for inhibiting Rheb, which in turn is an 
activator of mTOR.  By up-regulating REDD1 via VDR, vitamin D3 is thought to inhibit mTOR and 
thus its ability to phosphorylate S6K and 4EBP.19  In fact, Lisse et al. saw a 50% reduction in cellular 
proliferation of osteoblasts in response to calcitriol treatment.20  They determined this to be an 
effect of the demonstrated increase in REDD1 protein, resulting in a decrease in phosphorylation 
of S6K. 
 
Figure 1.2 Vitamin D3 and the mTOR pathway 
 
The described vitamin D – mTOR pathway is just a small segment of a much larger signal 
transduction picture.  This pathway shares downstream targets of the RAS-RAF-MEK-ERK and 
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PI3K/AKT pathways (Figure 1.3).21  Ras is a GTPase that is active when bound to GTP, and inactive 
when bound to GDP.  When activated, Ras induces translocation and phosphorylation of RAF, 
resulting in its activation.  Activated RAF then phosphorylates MEK, which phosphorylates 
extracellular signal-regulated kinases 1 and 2 (ERK1/2).  ERK1/2 can then activate mTOR.  Ras is 
also capable of activating phosphinositide-3 kinase (PI3K).  PI3K phosphorylates 
phosphatidylinositol bisphosphate (PIP2), forming PIP3, which activates protein kinase B (AKT).  
AKT is a kinase that is responsible for phosphorylating several proteins, including TSC 2.  This 
phosphorylation inhibits TSC1 and TSC2, preventing them from down-regulating Rheb, which can 
potentially lead to the activation of mTOR.  Therefore, Ras can indirectly activate mTOR through 
both of these pathways, contributing to increased cell growth and proliferation.  
 
Figure 1.3 RAS activation of mTOR via RAF/MEK/ERK (a) and PI3K/AKT (b) 
 
 
Indeed, both pathways were shown to be involved synergistically in the development of 
esophageal cancer.  Wei and Xu showed that phosphorylation of both AKT and ERK was increased 
in cancer patients.22  Interestingly, in many cancers, and as observed in our laboratory in human 
BCC tissue, a gain of function mutation is often seen in Ras.23  Our lab also reported an increase 
in expression of Ras mRNA in cancer tissue.  Over-activity of Ras signaling pathways may 
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overwhelm any inhibition from vitamin D3 supplementation via VDR/REDD1/mTOR signaling.  To 
make matters worse, oncogenic Ras may also reduce the expression of VDR.  Rozenchran et al. 
found that over-expression of Ras led to reduced levels of VDR due to mRNA instability.24  
Considering all of these factors collectively may help explain why the effectiveness of vitamin D3 
treatment is so inconsistent in clinical studies. 
Another pathway involved in BCC progression is the Hedgehog (HH) pathway (Figure 1.4).  
Patched1 (PTCH1) is a membrane receptor that binds to and inhibits Smoothened (SMO).  Sonic 
hedgehog protein (HH) disrupts this inhibition, allowing SMO to activate Gli proteins.  These 
proteins are transcription factors that then up-regulate genes involved in cellular proliferation.  
Mutations in this pathway, such as those that destroy the ability of PTCH1 to inhibit SMO, are the 
most common found in basal cell carcinoma.25  
 
Figure 1.4 The Hedgehog pathway 
 
 
In a second mechanism of the anti-cancer effects of vitamin D3, Uhmann et al. showed 
that calcitriol inhibits the HH pathway in a VDR-independent fashion by inhibiting SMO directly.26  
Tang, et al. disagree with this finding, on the basis of the form of vitamin D3 that is responsible 
for the inhibition of SMO.  They showed that only the non-hydroxylated vitamin D3, 
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cholecalciferol, could inhibit cellular proliferation.27  They also showed that cholecalciferol could 
reduce Gli1 mRNA, but the hydroxylated forms could not.   
In contrast to the studies by Uhmann and Tang, Teichert et al. found that calcitriol is 
involved in the VDR-dependent gene down-regulation of several of the hedgehog signaling 
pathway proteins.8  They also demonstrated that in the absence of VDR several of these genes 
were over-expressed.  Despite their disagreement on the mechanism involved, these studies 
make a strong argument for the inclusion of vitamin D3 in the treatment of basal cell carcinoma. 
Complicating the picture further, Wang et al. showed that activation of the mTOR 
pathway is capable of activating Gli proteins.27  This activation was shown to come from S6K and 
occurred in the absence of SMO, signifying the complex inter-relationship of the hedgehog and 
RAS/PI3K pathways.  This data was supported by another study in which a RAS/RAF pathway 
inhibitor was able to decrease Gli1 mRNA and protein expression.28  Furthermore, in a study 
published in 2013, researchers demonstrated that mice with RAS mutations required Gli for the 
formation of pancreatic cancer.29  They also found that RAS up-regulated the expression of HH, 
thus resulting in the activation of Gli.   
Mutations resulting in dysfunction of the HH pathway are the most common in BCC.  
However, as mentioned, they are often not the only mutations present.  Up-regulation of RAS or 
other oncogenes may negate the protective effect of vitamin D3 by overwhelming it and/or 
circumventing it.  This complex relationship stresses the importance of dual-pathway inhibitors 
in the treatment of cancer.  A compound that is capable of down-regulating aspects of both 
pathways could have tremendous benefit in the treatment of this form of cancer. 
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Despite its promise in vitro, vitamin D3 has yet to be proven effective in the clinical 
treatment of basal cell carcinoma.  In a personal communication between clinical practitioners 
and our laboratory, the need for more research into the molecular mechanisms involved in this 
treatment was discussed.  If supplementation is not beneficial perhaps it should no longer be 
prescribed.  Previous work in our laboratory involved comparison of gene expression in cancer, 
proximal, and distal tissue taken from the head and neck regions of human patients.  Our 
research indicated that genes involved in both the metabolism and signaling of vitamin D3 were 
up-regulated in cancer tissue.  Whether this is an innate defense against cancer, an effect of the 
cancer itself, or a combination of the two is yet to be determined. 
 
Specific Aim  
In addition to its role in bone mineralization and calcium homeostasis, Vitamin D3 has 
been implicated as a major regulator of cellular proliferation and differentiation.  The anti-
proliferative impact of Vitamin D3 is observed in clinical studies of breast and colon cancer, where 
vitamin D3 treatment is generally positive.  However, clinical data on vitamin D3 treatment of 
basal cell carcinoma (BCC) is lacking and inconclusive at best.  Because the majority of the in vitro 
studies in support of the protective effects of vitamin D3 in onset and progression of cancer were 
not performed in skin cells these findings may not be applicable to BCC.  Unfortunately, the non-
metastatic nature of BCC makes cell lines difficult to grow in culture.30  The goal of this study is 
to determine the impact of vitamin D3 on proliferation of an immortalized human keratinocyte 
cell (HaCaT), a model for the basal layer of the skin.  The HaCaT cells were spontaneously 
immortalized in vitro without transformation.  Their name references their Human Adult origin, 
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and their immortalization treatment of low Calcium and high Temperature.  The HaCaT cells 
exhibit normal differentiation markers and are non-tumorigenic.31  
Previous data in our laboratory indicate that the Hedgehog and mTOR-signaling pathways 
are activated in BCC tissue, despite increased expression of active vitamin D3.23  Therefore, I 
hypothesize that vitamin D3 treatment will increase proliferation of HaCaT cells by modulating 
the mTOR-signaling pathway and failing to inhibit the Hedgehog pathway.  Thus, vitamin D3 
treatment of skin cancer is ineffective and potentially detrimental.  This hypothesis will be tested 
by the following specific aims: 
1. To determine the impact of calcitriol and cholecalciferol on proliferation of HaCaT 
cells 
2. To dissect the molecular mechanism by which vitamin D3 supplementation alters the 
proliferation of HaCaT cells. 
10 
 
CHAPTER 2: Materials and Methods 
 
Cell Culture 
Human keratinocyte (HaCaT) cells were obtained from AddexBio.  Cultures were grown in 
Gibco DMEM High Glucose media supplemented with 10% FBS and antibiotics.  Cells were 
subcultured approximately twice weekly.  Media was purchased from Life Technologies. 
 
Treatment 
Calcitriol was purchased from Sigma Aldrich.  A 10-5 M stock solution was prepared in 
ethanol.  Cholecalciferol was purchased from Fisher Scientific.  A 1 M stock solution was prepared 
in ethanol.  Ten-fold serial dilutions were made from each stock.  Treatments were prepared 1% 
v/v in complete media.  Concentrations tested were 10-8  M and 10-7  M calcitriol, and 5x10-6  M 
and 10-5  M  cholecalciferol, as found in the literature.12 
5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) was purchased from 
Toronto Research Chemicals.  This molecule phosphorylates AMPK, mimicking low energy status 
([ATP]/[AMP]), which then results in inhibition of proliferation.32  It will be used as a positive 
control, as vitamin D3 inhibits proliferation independently of AMPK.  A 1 M stock solution was 
prepared in DMSO.  Ten-fold serial dilutions were made.  Treatments were prepared 1% v/v in 
complete media.  Concentrations tested were 10-4 M and 10-3 M, as found in the literature.32 
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WST-1 Cell Proliferation Assay 
 WST-1 cell proliferation reagent was purchased from Roche.  Viable, proliferating cells 
express active mitochondrial dehydrogenases.  This assay exploits the activity of these enzymes 
to compare proliferation of cells following different treatment conditions.  The enzymes cleave 
tetrazolium salts in the WST-1 reagent to produce formazan, a dye that absorbs at 420-480 nm.  
The absorbance directly correlates to the number of viable cells in the sample. 
 Cells were plated in 96-well tissue culture-treated plates at a concentration of 4000 cells 
per well and allowed to recover overnight.  The next day, media was replaced with the treatments 
listed in Table 2.1.  After 24 or 48 hours, treatment media was replaced with complete media 
containing 10% WST-1 reagent.  Three wells were reserved for blanks, in which no cells had been 
plated.  Following four hours of incubation at 37°C the absorbance was read at 450 nm.  Average 
blank absorbance was subtracted from all samples.  Changes in proliferation following vitamin or 
AICAR treatment were compared to controls treated with vehicle alone.  Results are given as 
fold-change versus controls, with controls normalized to 1. 
 
Table 2.1 Treatment of HaCaT keratinocyte cells for MTT cell proliferation assay. 
EtOH Vehicle 1 µL EtOH 100 µL Media 
10 nM Calcitriol 1µL 1 µM Stock 100 µL Media 
100 nM Calcitriol 1 µL 10 µM Stock 100 µL Media 
5 µM Cholecalciferol 1 µL 500 µM Stock 100 µL Media 
10 µM Cholecalciferol 1 µL 1 mM Stock 100 µL Media 
DMSO Vehicle 1 µL DMSO 100 µL Media 
0.1 mM AICAR 1 µL 10 mM Stock 100 µL Media 
1 mM AICAR 1 µL 100 mM Stock 100 µL Media 
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RNA Isolation and cDNA Synthesis 
 Cells were plated in 6-well tissue culture-treated plates at a concentration of 5x104 cells 
per well and allowed to recover overnight.  The next day, media was replaced with the treatments 
listed in Table 2.2.  After 24 or 48 hours of treatment, cells were rinsed with PBS, and RNA was 
extracted using the TRIzol method (Life Technologies).  RNA concentrations were measured with 
the Nanodrop UV/Vis spectrophotometer.  Next, 1 µg of RNA was used to synthesize cDNA using 
the Promega ImProm-II™ Reverse Transcription System.  RNA was first incubated with random 
primers in a volume of 10 µL at 70°C for five minutes.  Next, master mix was added to each tube, 
which contained 4 µL 5x buffer, 4 µL MgCl2, 1 µL dNTPs, and 1 µL reverse transcriptase. Samples 
were placed in an Eppendorf thermocycler.  The reverse transcription (RT-PCR) program 
consisted of the following steps: 25°C for five minutes, 42°C for one hour, 70°C for 15 minutes, 
and a 4°C hold.  The reaction products were then purified with the Qiagen QIAquick® PCR 
Purification Kit.  From the four samples from each treatment group, the three with the highest 
concentrations were chosen to use for RealTime PCR. 
 
Table 2.2 Treatment of HaCaT keratinocyte cells for RNA isolation 
EtOH Vehicle 20 µL EtOH 2 mL Media 
100 nM Calcitriol 20 µL 10 µM Stock 2 mL Media 
10 µM Cholecalciferol 20 µL 1 mM Stock 2 mL Media 
 
Real-Time PCR 
 Primers were purchased from Sigma Aldrich and reconstituted as 100 µM Stocks.  
Working stocks consisted of 5 µM forward plus 5 µM reverse primer.  Primer sequences are listed 
in Table 2.3.  The LightCycler® 480 SYBR Green I Master kit from Roche was used to prepare 
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samples for qPCR.  Samples consisted of 12.5 µL MasterMix from the kit, 1 µL primer mix (0.75 
µL for 25OHase), 3 µL cDNA (30.3 ng for 24 hour samples, 41.55 ng for 48 hour samples) and 
DNAse-free water to 23 µL.  Reactions were performed in a Stratagene thermocycler, and 
consisted of a five minute 95°C pre-incubation step, followed fifty cycles of amplification (ten 
seconds at 95°C followed by 30-60 seconds at the annealing temperature listed in Table 2.3) after 
which SYBR Green fluorescence was measured.  A third segment generated dissociation curve 
data, and consisted of heating the samples to 95°C for one minute, cooling to the proper 
annealing temperature for 30-60 seconds, and then heating to 95°C again, while constantly 
measuring fluorescence.  Threshold cycle (Ct) values were collected.  First, data was compared 
to the average of the controls (ΔCt) and then calculated as fold-change versus controls (2-ΔCt).  
Data is presented with controls normalized to 1. 
 
Table 2.3 Real-Time PCR Primer Sequences and Annealing Temperatures 
Target Sequence Tm Annealing Temp 
VDR fwd CCAGTTCGTGTGAATGATGG 64.1 57.0 
VDR rev GTCGTCCATGGTGAAGGA 62.3 57.0 
25OHase fwd GGCAAGTACCCAGTACGG 60.6 55.0 
25OHase rev AGCAAATAGCTTCCAAGG 57.0 55.0 
1αOHase fwd TGTTTGCATTTGCTCAGA 59.0 59.0 
1αOHase rev CCGGGAGAGCTCATACAG 61.0 59.0 
24OHase fwd GCAGCCTAGTGCAGATTT 58.1 55.0 
24OHase rev ATTCACCCAGAACTGTTG 55.7 55.0 
Gli1 fwd CTCCCGAAGGACAGGTATGTAAC 64.5 57.0 
Gli1 rev CCCTACTCTTTAGGCACTAGAGTTG 62.3 57.0 
REDD1 fwd GGTCACTGAGCAGCTCGAA 64.6 63.0 
REDD1 rev CCTGGACAGCAGCAACAGT 64.3 63.0 
KRAS fwd AAACTTGTGGTAGTTGGAGCTGG 55.3 50.0 
KRAS rev TGATTCTGAATTAGCTGTATCGTCAA 53.2 50.0 
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Protein Isolation and Quantification 
 Cells were plated in 100 mm tissue culture-treated dishes at a concentration of 5x105  cells 
per dish and allowed to recover overnight.  The next day, media was replaced with the treatments 
listed in Table 2.4.  After 24 or 48 hours of treatment, plates were rinsed with PBS, and cells were 
incubated in 700 µL lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Triton X-100, 1 mM 
EDTA, 1 mM EGTA, 1 mM PMSF, 0.1% SDS, 0.5% sodium deoxycholate, 1x protease inhibitor) for 
30 minutes at 4°C.  Following incubation, cells were collected with a cell scraper and placed at -
80°C overnight.  Following freeze-thaw, lysates were spun to remove pellet and then 
concentrated to <100 µL in 10 kDa spin column concentration units.  Concentrations were 
determined using the Pierce BCA Assay Kit.  Samples were prepared in Laemmli buffer and heated 
to 70°C for 5 min before running SDS PAGE. 
 
Table 2.4 Treatment of HaCaT keratinocyte cells for protein isolation. 
EtOH Vehicle 100 µL EtOH 10 mL Media 
100 nM Calcitriol 100 µL 10 µM Stock 10 mL Media 
10 µM Cholecalciferol 100 µL 1 mM Stock 10 mL Media 
DMSO Vehicle 100 µL DMSO 10 mL Media 
1 mM AICAR 100 µL 100 mM Stock 10 mL Media 
 
SDS PAGE and Western Blot 
 50 µg of whole cell extract samples were separated by SDS polyacrylamide gel 
electrophoreses (PAGE) using 4-15% or 10% Criterion™ TGX Stain-Free™ Precast gels (Bio-Rad).  
These gels were run at 250 V until the dye front reached the bottom of the gel (approximately 
thirty minutes).  They were then activated in the Bio-Rad Gel Doc™ EZ Imager, using the Image 
Lab™ software prior to being transferred onto nitrocellulose membrane at 75 V for 15 minutes.  
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The activation step involves the UV linkage of trihalo compounds in the precast gels to tryptophan 
residues in the proteins.  This produces fluorescence that can be detected by the imaging 
software.  The membranes were then imaged post-transfer to observe transfer efficiency.  After 
transfer membranes were blocked in 5% milk for 45-60 minutes.  Membranes were then 
incubated overnight in primary antibody solutions of TBS-Tween containing 5% BSA and sodium 
azide (Table 2.5).  HRP-conjugated secondary antibody solutions were prepared in TBS-Tween 
containing 5% BSA.  Blots were first probed with phospho-antibodies, followed by a stripping step 
(Restore™ Thermo Scientific) before probing with their total protein-specific antibody 
counterparts.  Blots were incubated with SuperSignal® West Pico or Femto chemiluminescent 
substrate (Thermo Scientific) before detection in the gel imager using the Quantity One® 1-D 
Analysis software.  Bands were detected and quantified with the Image Lab™ software.  The 
change in phosphorylation of three proteins of interest was calculated.  Results are given as fold-
change versus controls, with controls normalized to 1. 
 
Table 2.5 Antibodies used in Western Blot 
Target Vendor Catalog # Dilution Species 
phospho-4EBP, Thr 37/46 Cell Signaling 236B4 1:1000 Rabbit 
Total 4EBP Cell Signaling 9644 1:1000 Rabbit 
phospho-p70-S6K, Thr 389 Cell Signaling 9206 1:1000 Mouse 
Total p70-S6K Cell Signaling 2708 1:1000 Rabbit 
phospho-mTOR, Ser 2448 Cell Signaling 5536 1:1000 Rabbit 
Total mTOR Cell Signaling 2983 1:1000 Rabbit 
Anti-rabbit Santa Cruz Sc-2301 1-10,000 Goat 
Anti-mouse Santa Cruz Sc-2302 1:10,000 Goat 
 
Statistical Analysis 
A t test was performed to analyze all data.  A p value of less than 0.05 was considered significant.
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CHAPTER 3: Results 
WST-1 CELL PROLIFERATION ASSAY 
 HaCaT cells were treated for 24 or 48 hours with two forms of vitamin D3, calcitriol and 
cholecalciferol.  Results presented are from three independent experiments.  Following 24 hours 
of treatment 100 nM calcitriol increased cellular proliferation significantly (p = 0.03).  The 
absorbance at 450 nm increased by 19%, which directly correlates to a 19% increase in viable 
cells.  The other three treatment groups at this time point were not significantly different from 
controls (Figure 3.1).  Following 48 hours of treatment, all four groups had a significant increase 
in proliferation versus controls (p < 10-5).  10 nM and 100 nM Calcitriol increased proliferation by 
23% and 25%, respectively.  5 µM and 10 µM cholecalciferol increased proliferation by 29% and 
32%, respectively (Figure 3.2). 
 HaCaT cells were treated for 24 or 48 hours with AICAR.  Results presented are from three 
independent experiments.  Following 24 hours of treatment 1 mM AICAR decreased cellular 
proliferation significantly by 32% (p < 10-5) (Figure 3.3).  After 48 hours of treatment, both 
treatment groups had a significant decrease in proliferation versus controls; 0.1 mM AICAR 
decreased proliferation by 14% (p = 0.004), and 1 mM AICAR decreased proliferation by 42% (p 
< 10-10) (Figure 3.4). 
 
REAL-TIME PCR 
HaCaT cells were treated in with 100 nM calcitriol, 10 µM cholecalciferol, or EtOH vehicle 
for 24 or 48 hours.  Isolated RNA was used to create cDNA, which was then used to perform Real-
time analysis of several genes of interest.  Dissociation curves were analyzed for all genes to 
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exclude amplification results attributed to the presence of primer dimers.  The 25OHase reaction 
was repeated with 25% less primer to remove primer dimer amplification.  Genes tested were 
the vitamin D3 metabolizing genes (25OHase, 1αOHase, and 24OHase), three genes hypothesized 
to be affected by vitamin D3 treatment (VDR, REDD1, and Gli1), and Ras.  Ras was chosen because 
previous data from our laboratory showed an increased in Ras expression alongside increases in 
vitamin D activating enzymes in BCC tissue.  We wanted to determine whether or not this was 
directly caused by an increase in active vitamin D.  The samples called 24h Calcitriol-3 and 48h 
Calcitriol-2 both appear to be outliers, and each increases the average CT values for their groups.  
They have not been excluded, but will be addressed for each gene when necessary. 
 
25-OHase) Calcitriol treatment did not have an effect on expression of this gene following 24 
hours of treatment.  On average, the 48 hour treatment samples did not have an effect on this 
gene.  One sample, Calcitriol-3, had a two-fold increase, which brought the average close to that 
of controls.  When this sample is excluded the group has a reduction in 25OHase expression, 
although the data is not significant (p = 0.1).  Cholecalciferol appeared to increase expression 
following 24 hours, however the data is not significant.  Following 48 hours of treatment with 
cholecalciferol, 25OHase cDNA is significantly decreased compared to controls (p = 0.01) (Figure 
3.5). 
 
1α-OHase) Calcitriol treatment did not have an effect on expression of this gene.  Removal of 
both the 24 and 48 hour outliers brought the averages of these groups closer to that of controls.  
Cholecalciferol did not have an effect on expression following 24 hours.  However, following 48 
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hours of treatment with cholecalciferol, 1αOHase cDNA was significantly elevated above controls 
(p = 0.04) (Figure 3.6). 
 
24-OHase) Both calcitriol and cholecalciferol treatment increased the expression of this gene.  
The 24 hour data is not significant due to the variation within the groups, even when the outlier 
is excluded.  However, the trend is clearly evident and is supported by the several thousand-fold 
scale of the y-axis.  Following 48 hours of treatment the increase in expression with calcitriol and 
cholecalciferol treatment is significant (p < 0.015 and 10-5, respectively).  Excluding the outliers 
in the calcitriol treatment groups does not eliminate the significance (Figure 3.7). 
 
VDR) Calcitriol treatment did not have an effect on this gene.  Average fold-change was similar 
to controls, and exclusion of outliers brought the data even closer to controls.  Cholecalciferol 
treatment significantly increased VDR gene expression (p = 0.04).  This increase was gone after 
48 hours (Figure 3.8). 
 
REDD1)  24 hour treatment with calcitriol did not affect the expression of this gene, especially 
when the outlier was removed.  48 hour treatment indicated a trend of increased expression (p 
= 0.08), however the variation within the data prevented it from being significant, even with 
exclusion of the outlier.  Cholecalciferol treatment had a trend of increasing expression at 24 
hours.  This increase was significant following 48 hours of treatment (p = 0.01) (Figure 3.9). 
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Gli1)  Neither calcitriol nor cholecalciferol treatment had an effect on the expression of this gene 
following 24 or 48 hours of treatment (Figure 3.10). 
 
RAS) Neither calcitriol nor cholecalciferol treatment had an effect on the expression of this gene 
following 24 or 48 hours of treatment (Figure 3.11). 
 
WESTERN BLOT 
HaCaT cells were treated with Calcitriol, Cholecalciferol, or AICAR for 24 or 48 hours.  
Whole cell extract was isolated and analyzed by western blot.  Membranes were probed with 
antibodies for phosphorylated mTOR and total mTOR; phosphorylated S6K and total S6K; and 
phosphorylated 4EBP and total 4EB. 
 
mTOR) Both calcitriol and cholecalciferol 24 hour treatment resulted in a significant increase in 
phosphorylated mTOR (p = 0.04 and 0.02, respectively).  Calcitriol increased levels by 2.8 fold, 
while cholecalciferol increased levels by 2.3-fold.  Phosphorylation of mTOR returned to control 
levels after 48 hours (Figure 3.12). 
 
P70-S6K)  Both calcitriol and cholecalciferol treatment appeared to increase phosphorylation of 
S6K following 24 hours of treatment, however the data was not significant (p = 0.14 and 0.17, 
respectively).  The trend is gone following 48 hours of treatment (Figure 3.13).  Data are a 
combination of two western blots with the same samples. 
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4EBP)  Neither calcitriol nor cholecalciferol treatment significantly increased phosphorylation of 
4EBP following 24 hour treatment, however, a trend is evident.  After 48 hours of treatment, 
both forms of the vitamin significantly increased 4EBP phosphorylation status (p = 0.0008 and 
0.005, respectively) (Figure 3.14).  Calcitriol treatment resulted in a two-fold increase in 
phosphorylated 4EBP, while cholecalcitriol increased the levels by 2.5-fold.  Data are a 
combination of two western blots with the same samples. 
 
AICAR Treatment) As a control, cells were treated with 1 mM AICAR for 48 hour and whole cell 
extract was analyzed via western blot.  The same proteins were probed for as the vitamin D3 
treatment blots.  Treatment with AICAR resulted in a significant decrease in phosphorylation of 
all three proteins tested (pmTOR = 0.03, pS6K = 0.02, p4EBP = 0.04) (Figure 3.15).  The decrease is 
phosphorylation of mTOR was by 91%.  Phosphorylation of P70-S6K decreased by 55%.  
Phosphorylation of 4EBP decreased by 45%.  The data for 4EBP were a combination of two 
western blots with the same samples.
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Figure 3.1. Cellular proliferation following 24 hour treatment with vitamin D3.  HaCaT cells were 
treated for 24 hours with calcitriol (10 nM and 100 nM), cholecalciferol (5 µM and 10 µM), or 
vehicle.  Cells were then incubated with WST-1 reagent for four hours at 37°C.  Absorbance was 
read at 450 nM.  Results are presented as percentage versus controls.  A p-value of less than 0.05 
is considered significant.  Bars with different symbols are significantly different from each other. 
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Figure 3.2. Cellular proliferation following 48 hour treatment with vitamin D3.  HaCaT cells were 
treated for 48 hours with calcitriol (10 nM and 100 nM), cholecalciferol (5 µM and 10 µM), or 
vehicle.  Cells were then incubated with WST-1 reagent for four hours at 37°C.  Absorbance was 
read at 450 nM.  Results are presented as percentage versus controls.  A p-value of less than 0.05 
is considered significant.  Bars with different symbols are significantly different from each other. 
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Figure 3.3. Cellular proliferation following 24 hour treatment with AICAR.  HaCaT cells were 
treated for 24 hours with AICAR (0.1 mM and 1 mM) or vehicle.  Cells were then incubated with 
WST-1 reagent for four hours at 37°C.  Absorbance was read at 450 nM.  Results are presented 
as percentage versus controls.  A p-value of less than 0.05 is considered significant.  Bars with 
different symbols are significantly different from each other. 
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Figure 3.4. Cellular proliferation following 48 hour treatment with AICAR.  HaCaT cells were 
treated for 48 hours with AICAR (0.1 mM and 1 mM) or vehicle.  Cells were then incubated with 
WST-1 reagent for four hours at 37°C.  Absorbance was read at 450 nM.  Results are presented 
as percentage versus controls.  A p-value of less than 0.05 is considered significant.  Bars with 
different symbols are significantly different from each other. 
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Figure 3.5. 25-OHase transcript fold change following treatment with vitamin D3.  HaCaT cells 
were treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours (a,b) or 48 
hours (c,d).  Real-time PCR was performed using primers specific for 25-hydroxylase.  Changes 
in expression of this gene are presented as fold change relative to controls.  A p-value of less 
than 0.05 is considered significant.  Bars with different symbols are significantly different from 
each other. 
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Figure 3.6. 1α-OHase transcript fold change following treatment with vitamin D3.  HaCaT cells 
were treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours (a,b) or 48 
hours (c,d).  Real-time PCR was performed using primers specific for 1α-hydroxylase.  Changes in 
expression of this gene are presented as fold change relative to controls.  A p-value of less than 
0.05 is considered significant.  Bars with different symbols are significantly different from each 
other. 
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Figure 3.7. 24-OHase transcript fold change following treatment with vitamin D3.  HaCaT cells 
were treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours (a,b) or 48 
hours (c,d).  Real-time PCR was performed using primers specific for 24-hydroxylase.  Changes in 
expression of this gene are presented as fold change relative to controls.  A p-value of less than 
0.05 is considered significant.  Bars with different symbols are significantly different from each 
other. 
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Figure 3.8. VDR transcript fold change following treatment with vitamin D3.  HaCaT cells were 
treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours (a,b) or 48 hours 
(c,d).  Real-time PCR was performed using primers specific for the vitamin D receptor.  Changes 
in expression of this gene are presented as fold change relative to controls.  A p-value of less than 
0.05 is considered significant.  Bars with different symbols are significantly different from each 
other. 
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Figure 3.9. REDD1 transcript fold change following treatment with vitamin D3.  HaCaT cells were 
treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours (a,b) or 48 hours 
(c,d).  Real-time PCR was performed using primers specific for REDD1.  Changes in expression of 
this gene are presented as fold change relative to controls.  A p-value of less than 0.05 is 
considered significant.  Bars with different symbols are significantly different from each other. 
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Figure 3.10. Gli1 transcript fold change following treatment with vitamin D3.  HaCaT cells were 
treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours (a,b) or 48 hours 
(c,d).  Real-time PCR was performed using primers specific for Gli1.  Changes in expression of this 
gene are presented as fold change relative to controls.  A p-value of less than 0.05 is considered 
significant.  Bars with different symbols are significantly different from each other. 
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Figure 3.11. Ras transcript fold change following treatment with vitamin D3.  HaCaT cells were 
treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours (a,b) or 48 hours 
(c,d).  Real-time PCR was performed using primers specific for Ras.  Changes in expression of this 
gene are presented as fold change relative to controls.  A p-value of less than 0.05 is considered 
significant.  Bars with different symbols are significantly different from each other. 
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Figure 3.12. Change in phosphorylation of mTOR following treatment with vitamin D3.  HaCaT 
cells were treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours or 48 
hours.  Whole cell extract (50µg per sample) was compared by western blot analysis.  Blots were 
probed with antibody specific for phosphorylated mTOR (Ser 2448) and total mTOR.  Changes in 
phosphorylation of this gene are presented as fold change relative to controls.  A p-value of less 
than 0.05 is considered significant.  Bars with different symbols are significantly different from 
each other. 
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Figure 3.13. Change in phosphorylation of P70-S6K following treatment with vitamin D3.  HaCaT 
cells were treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours or 48 
hours.  Whole cell extract (50µg per sample) was compared by western blot analysis.  Blots were 
probed with antibody specific for phosphorylated P70-S6K (Thr 389) and total P70-S6K.  Changes 
in phosphorylation of this gene are presented as fold change relative to controls.  A p-value of 
less than 0.05 is considered significant.  Bars with different symbols are significantly different 
from each other. 
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Figure 3.14. Change in phosphorylation of 4EBP following treatment with vitamin D3.  HaCaT 
cells were treated with 100 nM calcitriol, 10 µM cholecalciferol, or vehichle for 24 hours or 48 
hours.  Whole cell extract (50µg per sample) was compared by western blot analysis.  Blots were 
probed with antibody specific for phosphorylated 4EBP (Thr 37/46) and total 4EBP.  Changes in 
phosphorylation of this gene are presented as fold change relative to controls.  A p-value of less 
than 0.05 is considered significant.  Bars with different symbols are significantly different from 
each other. 
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Figure 3.15. Change in phosphorylation of mTOR, P70-S6K, and 4EBP following treatment with 
AICAR.  HaCaT cells were treated with 1 mM AICAR or vehichle for 48 hours.  Whole cell extract 
(50µg per sample) was compared by western blot analysis.  Blots were probed with antibody 
specific for phosphorylated mTOR (Ser 2448) and total mTOR (a), phosphorylated P70-S6K (Thr 
389) and total P70-S6K (b), and phosphorylated 4EBP (Thr 37/46) and total 4EBP (c).  Changes in 
phosphorylation of this gene are presented as fold change relative to controls.  A p-value of less 
than 0.05 is considered significant.  Bars with different symbols are significantly different from 
each other. 
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CHAPTER 4: Discussion 
 The vast majority of research indicates that vitamin D3 has anti-proliferative effects in 
vitro.  These effects have even been shown in clinical studies of breast and colon cancer, and the 
results of vitamin D3 treatment are generally positive for these cancers.  Unfortunately, data is 
lacking and inconclusive in the treatment of basal cell carcinoma.  Perhaps one reason for the 
varied response to treatment for different tissues is the difference in exposure to UV light 
combined with the availability of vitamin D3 metabolizing enzymes.  The skin is unique because it 
has all of these, and thus it has the potential to synthesize active vitamin D3 de novo, as well as 
inactivate it when high levels are no longer desirable.  Because of this, it is necessary to perform 
cell culture experiments in skin cell models of basal cell carcinoma, and not cells from other 
tissues.  Unfortunately, experiments are difficult because BCC cells do not proliferate well in 
culture.  The HaCaT keratinocyte cell line, therefore, is a useful model for skin tissue because it is 
immortalized and grows rapidly in culture.   
 In the present study, HaCaT cells were treated with various concentrations of calcitriol or 
cholecalciferol for 24 or 48 hours.  As a positive control, cells were also treated with AICAR for 24 
or 48 hours, which significantly decreased proliferation relative to controls.  The AICAR results 
indicate that proliferation of these cells is capable of being inhibited despite high levels of growth 
factors in the media.  Interestingly, not only did treatments with both calcitriol and cholecalciferol 
fail to inhibit proliferation, they actually increased it.  Early research involving these cells 
indicated that high calcium concentrations may actually render calcitriol treatment proliferative, 
however current research rarely considers this.33,34  Calcium concentration in the skin is stratified 
and corresponds to the level of differentiation of the cells, with low levels in the stratum basale, 
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and high levels in the stratum granulosum.35  If high calcium correlates with a more differentiated 
phenotype, it seems counter-intuitive that high levels would also render calcitriol treatment 
proliferative, as differentiation is usually associated with growth cessation.  Analysis of the 
DMEM used in our experiments showed that our cell culture media contained 1.8 mM calcium, 
which corresponded to the high concentrations tested in these early experiments.  It should be 
noted that this is a common formulation used in many cell culture experiments, including those 
relevant to the current study.  Other early studies suggest that low, physiological concentrations 
of calcitriol promoted growth, however, the concentrations tested in the present study were 
higher than these and were expected to be inhibitory.36  Taking these older studies into 
consideration may make it feasible that vitamin D3 treatment may not inhibit growth under all 
conditions.  Based on these results, we decided to investigate key effectors in the mTOR and 
Hedgehog pathways to understand how their status may impact proliferation in our treatment 
groups. 
 Real time PCR was performed on cDNA from cells that were treated with calcitriol, 
cholecalciferol, and ethanol vehicle.  Calcitriol treatment had no effect on expression of the 
metabolizing 25-hydroxylase and 1α-hydroxylase genes, as it is an end product of their sequential 
reactions.  Cholecalciferol appeared to increase 25-hydroxylase mRNA following 24 hours of 
treatment (p = 0.1), and then significantly decrease it after 48 hours.  A significant increase in 1α-
hydroxylase was seen after 48 hours.  Taken together, the expression of these enzymes may 
correlate with sequential hydroxylation of cholecalciferol to form calcitriol. 
Both calcitriol and cholecalciferol treatment significantly increased 24-hydroxylase (the 
vitamin D3 inactivating enzyme) mRNA after 48 hours of treatment.  The 24-hydroxylase 
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promoter contains two vitamin D response elements (VDREs) that bind the vitamin D receptor.37  
The increase seen here verifies that both calcitriol and cholecalciferol successfully entered the 
cells and were capable of exerting an effect on gene expression via the vitamin D receptor (VDR).  
Additionally, this verifies that cholecalciferol was successfully hydroxylated by 25-hydroxylase 
and 1α-hydroxylase, as only calcitriol binds VDR.38  The thousand-fold increase in expression of 
this gene is too substantial to be ignored.  24-hydroxylase is often considered an oncogene 
because it results in the degradation of vitamin D3.39  Indeed, inhibition of 24-hydroxylase 
enhanced the anti-proliferative properties of calcitriol in prostate cancer cells.40  Perhaps the 
major up-regulation of this gene is also somehow responsible for the increase in proliferation 
seen here. Another point to consider is that any effects seen in this study may be an artifact of 
the limitations of cell culture.  24-hydroxylase inactivation of calcitriol and cholecalciferol in vivo 
results in their clearance from the body, while in vivo these products accumulate in the media.   
 While both forms of vitamin D3 were able to regulate 24-hydroxylase gene expression, 
only cholecalciferol had an effect on the VDR transcript.  Levels increased significantly with 24 
hours of treatment, and then returned to control levels after 48 hours (as protein concentration 
was most likely sufficient).  However, it cannot be directly inferred that the difference in 
expression of VDR mRNA between calcitriol and cholecalciferol treatment groups affected the 
activity of VDR protein.  REDD1 (a target of VDR transcription regulation) mRNA was significantly 
increased by cholecalciferol treatment after 48 hours.  However, the trend is also evident for 
calcitriol treatment (p = 0.08), so it is most likely that REDD1 mRNA is also increased in this group.  
Perhaps cholecalciferol treatment increased VDR expression, which allowed for a faster 
accumulation of REDD1, however, this conclusion needs further investigation. 
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 The most common mutations found in BCC are those affecting the Hedgehog pathway.  
Vitamin D3 is perhaps so compelling in the treatment of BCC because multiple studies suggest 
that calcitriol and/or cholecalciferol can inhibit activation of this pathway.  While some suggest 
that the inhibition comes at the level of blocking Smo, independent of the VDR, others say that 
calcitriol, via VDR, controls the expression of several of the genes involved.  Ultimately, all 
suggested means of inhibition result in a decrease in Gli1 mRNA.  Analysis of Real Time PCR data 
showed that neither calcitriol nor cholecalciferol treatment had any effect on the expression of 
Gli1 transcript in the current study.  One possible explanation for this is that both forms of vitamin 
D3 are incapable of inhibiting this pathway due to the cell culturing conditions.  It could be that 
the presence of growth factors override the ability of VDR to control the expression of genes in 
the pathway.  It is possible that another nutrient in the media is blocking the ability of calcitriol 
and/or cholecalciferol to bind to and inhibit Smo.  A second explanation may be that Gli1 mRNA 
can only be reduced when it is over-expressed in the first place.  No studies suggest any mutations 
in this pathway in HaCaT cells, so it can be assumed that this pathway is not over-active.  Testing 
this theory might involve the introduction of a deregulating mutation to Ptch or Smo, and then 
observation of the effects of vitamin D3 treatment on Gli1 mRNA expression.  Regardless of the 
cause, the absence of an effect on Gli1 transcript expression in the present study provides two 
important pieces of information.  First, it supports our findings that vitamin D3 treatment does 
not always inhibit proliferation of HaCaT cells.  Second, it shows that vitamin D3 treatment does 
not upregulate this pathway, and therefore it is not the cause of the increase in proliferation seen 
in our WST-1 assay. 
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 We also looked at the expression of Ras in response to calcitriol and cholecalciferol.  
Earlier research in our laboratory showed that Ras was up-regulated in cancer tissue, along with 
up-regulation of 1α-hydroxylase.  We wanted to confirm that the increase in Ras transcript was 
due to a malfunction of the cancer cells, and not somehow caused by increasing concentrations 
of calcitriol.  Real Time PCR data showed that calcitriol and cholecalciferol treatments had no 
effect of Ras expression. 
 Taken together, the results from Real Time PCR indicate that cholecalciferol is converted 
to calcitriol by 25-hydroxylase and 1α-hydroxylase.  Calcitriol is then able to bind to VDR, resulting 
in up-regulation of REDD1 and 24-hydroxylase.  REDD1 inhibits the mTOR pathway, so the 
increase in REDD1 we see should lead to inhibition of proliferation.  Neither calcitriol nor 
cholecalciferol inhibited the Hedgehog pathway, as determined by the lack of effect on Gli1 
expression.  While this may be partially responsible for the lack of inhibition on cell proliferation, 
it does not explain the increase in proliferation seen.  To further probe the cause of the 
dysfunction, we decided to investigate what is occurring downstream of REDD1.  To do so 
required the utilization of western blotting, as the signaling involves the phosphorylation status 
of key proteins, including mTOR, P70-S6K, and 4EBP. 
 HaCaT cells were treated with calcitriol, cholecalciferol, or ethanol vehicle for 24 or 48 
hours.  As a control, cells were also treated with AICAR or DMSO vehicle for 48 hours.  The 
increase in REDD1 was expected to result in a decrease in phosphorylation of mTOR, which would 
inhibit proliferation.  After 24 hours of treatment with both calcitriol and cholecalciferol we see 
a significant increase in phosphorylation of mTOR (Figure 3.12).  After 48 hours the 
phosphorylation of mTOR returns to control levels.  Phosphorylation of mTOR results in its 
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activation, which leads to downstream signaling that encourages cellular proliferation.  This helps 
explain the increase in proliferation seen in the WST-1 assay.   
To probe whether the activation of mTOR had effects downstream, we also looked at the 
phosphorylation of its targets, P70-S6K and 4EBP.  Neither treatment had a significant effect on 
P70-S6K phosphorylation, however an increasing trend is seen at 24 hours (p < 0.2).  The 
treatment groups return to levels of controls after 48 hours (Figure 3.13).  Next we looked at 
4EBP.  Neither treatment had an effect on phosphorylation of this protein after 24 hours.  
However, after 48 hours of treatment both calcitriol and cholecalciferol had a significant increase 
in 4EBP phosphorylation.  This clearly helps to explain the increase in cellular proliferation we see 
in response to treatment with both forms of vitamin D3.  Phosphorylation of 4EBP results in its 
inactivation, and removes its inhibition of the translation initiation factor, 4E.  This results in the 
recruitment of the translation machinery and assembly of the ribosome.  Therefore, 4EBP is 
essential in controlling the rate of translation in the cell, and its inactivation removes inhibition 
of protein synthesis.  This, in turn, can contribute to an increase in cellular proliferation. 
As mentioned, we also treated cells with AICAR as a positive control.  AICAR 
phosphorylates AMPK, which is a sensor of cellular energy status.  An increase in p-AMPK signals 
a decrease in ATP/ADP ratio, and results in inhibition of proliferation.  One way this happens is 
by direct control of mTOR activation.  Protein analysis via western blot yielded a significant 
decrease in phosphorylation of mTOR, P70-S6K, and 4EBP following 48 hours of AICAR treatment 
(Figure 3.15).  This is essential to explain the decrease in proliferation due to AICAR, but not 
Vitamin D3, treatment seen in the WST-1 assay.  When the mTOR pathway is inhibited 
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proliferation can also be inhibited.  However, more research is needed in order to prove causality, 
because AICAR may control other pathways as well. 
Under conditions in our laboratory, vitamin D3 treatment increased the proliferation of 
HaCaT cells.  AICAR treatment showed that cell proliferation was capable of being inhibited in 
the media formulation used.  Neither form of Vitamin D3 decreased Gli1 transcript levels, 
indicating that they do not inhibit the Hedgehog pathway in these conditions.  This helped us 
understand why proliferation was not inhibited, but to explain why it was increased required 
analysis of the mTOR pathway.  AICAR treatment also showed that the mTOR pathway was intact, 
and inhibition of this pathway may inhibit proliferation.  Real-time PCR data showed that REDD1 
transcript was increased by cholecalciferol, and most likely by calcitriol as well (p = 0.08).  An 
increase in REDD1 should result in a decrease in mTOR phosphorylation, but we saw the opposite 
effect.  Therefore, the dysfunction seen in the inhibition of proliferation by Vitamin D3 must be 
presenting at the level of the inhibition of mTOR by REDD1.  Somehow calcitriol and 
cholecalciferol treatment either block the negative regulation of REDD1 on mTOR, or they impact 
another pathway that activates mTOR, and this activity overwhelms the negative regulation 
coming from REDD1.  Either way, the negative regulation of vitamin D3 on cellular proliferation is 
reversed due to insensitivity of mTOR to REDD1, and activation of the mTOR pathway. 
The results presented here suggest that vitamin D3 treatment increases proliferation of 
HaCaT cells under conditions in our laboratory.  This goes against most current research, which 
generally supports the anti-proliferative activity of vitamin D3.  Early research from the 1990’s 
suggested that high calcium concentrations may render calcitriol proliferative in these cells.  Our 
media contains 1.8 mM calcium, which corresponds to these high concentrations.  Therefore, the 
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dysregulation seen in the current study may be occurring due to an interaction between vitamin 
D3 and extracellular calcium.  However, several current studies culture cells in media containing 
1.8 mM calcium, yet still show that vitamin D3 has anti-proliferative properties.12,25 
It should be noted that this research does not condemn the use of vitamin D3 in cancer 
treatment or nutritional supplementation.  The effects vitamin D3 has on bone remodeling, 
immune function, and cell proliferation are vast and varied.  Normal, physiological concentrations 
of vitamin D3 are essential for proper functioning of cells, tissues, organs, and organ systems.  The 
ability to increase concentrations of vitamin D3 are also essential to protect against stress from 
the environment, such as UV rays.  However, this research shows that over-supplementation is 
not always beneficial.  Under HaCaT cell culture conditions in our laboratory, too much of a good 
thing turned out to be bad. 
 
Future Directions 
 In order to determine whether these results are affected by the formulation of the media, 
more experiments are required.  The next logical experiments would include serum deprivation 
to control for the effects of growth factors in the media.  Also desirable are experiments 
performed in the presence of lower concentrations of calcium. 
 One interesting question that arose from this project is why treatment had no effect on 
control of the Hedgehog pathway.  I hypothesize that vitamin D3 only inhibits Gli1 expression 
when it is over-expressed.  Testing this would involve either mutating PTCH or Smo, or 
transgenically over-expressing Gli1.  Doing so would help explain why our data disagree with what 
so many other studies suggest. 
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 The main concern of the current study is that vitamin D3 treatment increased proliferation 
of these cells, when we expected to see a decrease.  I hypothesize that this is caused by the 
extreme increase in 24-hydroxylase gene expression.  The skin is unique in its ability to synthesize 
and activate vitamin D3, because it is directly exposed to the UV light and it possesses all of the 
enzymes required for its conversion to calcitriol.  This can lead to a rapid accumulation of 
calcitriol, which other organs do not experience.  Other organs gradually obtain calcitriol from 
the blood, after it has been activated in the liver and kidneys.  For this reason, the skin also needs 
to be able to inactivate calcitriol rapidly.  Treating skin cells with pharmacologic doses of vitamin 
D3 resulted in a several thousand-fold increase in 24-hydroxylase.  I propose that in addition to 
inhibition of calcitriol, 24-hydroxylase has other oncogenic effects.  I hypothesize that 24-
hydroxylase or its product, 1α,24,25(OH)3 D3, is involved in one or more signal transduction 
pathways that lead to increased proliferation.  Testing this would first involve silencing 24-
hydroxylase and looking for proliferation inhibition following vitamin D3 treatment.  Determining 
its direct effect would involve the analysis of the status of several signaling pathways, including 
the RAS/RAF/MEK/ERK and PI3K/AKT pathways. 
 The present study needs to be repeated in primary cells to confirm that our results are 
true under even more accurate physiological conditions.  While HaCaT cells are a good model for 
the skin, they are not the best.  Unfortunately, however strong an in vitro model may be, the 
results obtained may never truly replicate the influence of organ systems in vivo.  Due to the 
limitations of cell culture, the only true way to test our results is to sample human tissue. 
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 Vitamin D3 treatment has long been considered in the treatment of cancer due to its well-
documented anti-proliferative effects in vitro.  While clinical studies have been positive in other 
cancers, results are inconclusive in cases of basal cell carcinoma.  To better understand the 
reasons underlying this disconnect, this study employs an immortalized human keratinocyte cell 
line (HaCaT) to observe the effects of vitamin D3 treatment on cellular proliferation.  The results 
show that both activate vitamin D3 (calcitriol) and its precursor (cholecalciferol) increase 
proliferation of these cells.  Real-time PCR and western blot data indicate that the mTOR pathway 
becomes activated despite increased VDR signaling and expression of REDD1.  Treatment was 
also unable to inhibit the Hedgehog signaling pathway.
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